MRCC deploys CTT's Calmare Pain Therapy Treatment medical device

Competitive Technologies, Inc. (NYSE Amex:CTT) announced that McKinney Regional Cancer Care Center, a private physician oncology practice based in McKinney, TX, is the first cancer center in Texas treating with CTT's Calmare^® Pain Therapy Treatment medical device. Patients suffering from pain related to cancer are being treated under the direction of medical oncologist Dennis Birenbaum, M.D.

"We are excited to have McKinney Regional Cancer Care Center, with locations in the Dallas/Ft. Worth area, evaluating our Calmare Therapy Treatment device," said John B. Nano, CTT's Chairman, President, and CEO. "We are all committed to improving cancer patients' quality of life. We know that our Calmare device is the only highly effective treatment for chemotherapy-induced peripheral neuropathy (CIPN) without the harmful, adverse side effects of narcotic pain killers. From the growing body of evidence-based patient outcomes we know that in addition to CIPN, our Calmare device successfully treats chronic neuropathic pain resulting from cancer, cancer chemotherapy, phantom limb syndrome, failed back surgery, sciatica, spinal stenosis, shingles and other maladies." 

"We are pleased to offer this treatment option for our patients who suffer from severe and intractable pain," said McKinney Regional Cancer Care's Dr. Birenbaum. "Suffering from cancer and other diseases is difficult enough. We are already seeing the benefit to patients from using the Calmare pain therapy device. It is rewarding to administer and observe this new and effective pain treatment helping our patients avoid the negative side effects of narcotic painkillers and improve their quality of life."

The non-invasive Calmare pain therapy device uses the biophysical "Scrambler Therapy" technology, which was developed in Italy by CTT's client, Professor Giuseppe Marineo. CTT's partner, GEOMC Co. Ltd. of Seoul, Korea is manufacturing the Calmare device, which has U.S. FDA clearance and European Union CE Mark clearance for sales.